ANI Pharma (ANIP) Tops Q3 EPS by 12c, Reaffirms Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2018 Results and Reaffirms Guidance
November 6, 2018 8:30 AM ESTBAUDETTE, Minn., Nov. 6, 2018 /PRNewswire/ --
For the third quarter 2018:
Record net revenues of $50.7 million, an increase of 5% as compared to the same period in 2017 GAAP net income of $5.0 million and diluted GAAP earnings per share of $0.42 Adjusted non-GAAP EBITDA of $21.4 million Adjusted non-GAAP diluted earnings per share of $1.29ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported its financial results for the three and nine months ended September 30, 2018 and reaffirmed its 2018 financial guidance. The Company will... More
